Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company’s main growth driver. For 1Q17, ANIK reported that MONOVISC sales grew +24% worldwide vs. 1Q16, with U.S. sales increasing by +26%.
Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company's main growth driver. For 1Q17,...
Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company’s main growth driver. For 1Q17, ANIK reported that MONOVISC sales grew +24% worldwide vs. 1Q16, with U.S. sales increasing by +26%.
Copy to clipboard 
